KCNQ2

KCNQ2

Overview

```mermaid
flowchart TD
classDef gene fill:#0a1f0a,stroke:#4caf50
classDef protein fill:#0a1929,stroke:#2196f3
classDef disease fill:#2d0f0f,stroke:#e91e63
classDef pathway fill:#3e2200,stroke:#ff9800
classDef mechanism fill:#1a0a1f,stroke:#9c27b0
classDef therapeutic fill:#e0f2f1,stroke:#009688
KCNQ2["KCNQ2"] -->|"implicated_in"| neurodegeneration["neurodegeneration"]
KCNQ2["KCNQ2"] -->|"associated_with"| GENES["GENES"]
KCNQ2["KCNQ2"] -->|"therapeutic_target"| SCN1A["SCN1A"]
KCNQ2["KCNQ2"] -->|"therapeutic_target"| MTOR["MTOR"]
KCNQ2["KCNQ2"] -->|"therapeutic_target"| RELN["RELN"]
KCNQ2["KCNQ2"] -->|"therapeutic_target"| Aging["Aging"]
KCNQ2["KCNQ2"] -->|"therapeutic_target"| Als["Als"]
KCNQ2["KCNQ2"] -->|"therapeutic_target"| Neuroinflammation["Neuroinflammation"]
KCNQ2["KCNQ2"] -->|"therapeutic_target"| Epilepsy["Epilepsy"]
KCNQ2["KCNQ2"] -->|"therapeutic_target"| Autism["Autism"]
KCNQ2["KCNQ2"] -->|"therapeutic_target"| Ms["Ms"]
KCNQ2["KCNQ2"] -->|"therapeutic_target"| Inflammation["Inflammation"]
KCNQ2["KCNQ2"] -->|"therapeutic_target"| Mtor["Mtor"]
KCNQ2["KCNQ2"] -->|"therapeutic_target"| Epigenetic["Epigenetic"]
KCNQ2["KCNQ2"] -->|"therapeutic_target"| Synaptic_Plasticity["Synaptic Plasticity"]
KCNQ2["KCNQ2"] -->|"regulates"| MECP2["MECP2"]
KCNQ2["KCNQ2"] ==>|"activates"| ERK["ERK"]
KCNQ2["KCNQ2"] -->|"regulates"| GENES["GENES"]
KCNQ2["KCNQ2"] ==>|"activates"| RUNX1["RUNX1"]
KCNQ2["KCNQ2"] -->|"regulates"| HDAC2["HDAC2"]
KCNQ2["KCNQ2"] -->|

KCNQ2

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KCNQ2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>KCNQ2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>20q13.33</td>
</tr>
<tr>
<td class="label">Genomic Coordinates</td>
<td>chr20:62,030,000-62,100,000 (GRCh38)</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>~50 kb</td>
</tr>
<tr>
<td class="label">Number of Exons</td>
<td>19 coding exons</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>~2.4 kb coding sequence</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>844 amino acids</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Voltage-gated potassium channel (Kv7 family)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (neurons throughout forebrain, highest in cortex, hippocampus, brainstem)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>602235</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>O43726</td>
</tr>
<tr>
<td class="label">Disorder</td>
<td>Variant Type</td>
</tr>
<tr>
<td class="label">KCNQ2 encephalopathy</td>
<td>Loss-of-function (missense, nonsense, truncating)</td>
</tr>
<tr>
<td class="label">Benign familial neonatal seizures (BFNS)</td>
<td>Gain-of-function (missense)</td>
</tr>
<tr>
<td class="label">Early-onset epileptic encephalopathy</td>
<td>Severe loss-of-function</td>
</tr>
</table>

[KCNQ2](/entities/kcnq2) encodes Kv7.2, a voltage-gated potassium channel subunit that forms the M-current, a critical regulator of neuronal excitability. Pathogenic variants in [KCNQ2](/entities/kcnq2) cause two distinct disorders depending on the functional consequence: gain-of-function variants produce benign familial neonatal seizures (BFNS), while loss-of-function variants cause KCNQ2 encephalopathy, a severe developmental and epileptic encephalopathy.

[KCNQ2](/entities/kcnq2) is one of the most commonly identified genes in early-onset neonatal epilepsies, accounting for approximately 5-10% of cases. The gene is also notable because many patients with KCNQ2 encephalopathy experience significant seizure improvement in the first 1-3 years of life, distinguishing it from other DEEs["@kcnq2gene2022"].

Gene Information

Structure and Function

Kv7.2 Protein Structure

Kv7.2 contains six transmembrane segments (S1-S6):

• S1-S4: voltage-sensing domain — S4 carries the positive charges that detect membrane potential
• S5-S6: pore-forming domain — establishes K+ selectivity
• C-terminal domain (long): contains sites for protein-protein interactions, modulation by calmodulin, and regulation by phosphoinositides (PIP2)

The M-Current

The M-current (named for its inhibition by muscarinic acetylcholine receptor activation) is a non-inactivating K+ current that activates at voltages near the threshold for action potential firing. It serves as a "brake" on neuronal excitability:

Pathophysiology

Gain-of-Function Variants (BFNS)

Gain-of-function variants increase M-current amplitude or shift activation to more negative voltages. This hyperpolarizes neurons, making them harder to fire. The result is benign familial neonatal seizures (BFNS) — self-limited seizures that typically resolve within the first year of life with normal neurodevelopment.

Loss-of-Function Variants (KCNQ2 Encephalopathy)

Loss-of-function variants reduce M-current, leading to:

• Depolarized resting potential — closer to action potential threshold
• Increased neuronal firing — neurons require less input to generate spikes
• Reduced spike frequency adaptation — neurons fire more sustained trains
• Network hyperexcitability — downstream circuits become overactive

• Developmental upregulation of KCNQ3 (compensatory increase in Kv7.3)
• Increased PIP2 levels with maturation
• Activity-dependent circuit refinement

Disease Associations

Genotype-Phenotype Correlations

• Missense variants in the pore domain: often severe
• Truncating variants (nonsense/frameshift): typically severe, may be dominant-negative
• Missense variants in C-terminal domain: variable severity, may respond better to treatment
• Specific variants (e.g., R214Q, R229W): well-characterized genotype-phenotype relationships

Therapeutic Approaches

Potassium Channel Openers

Ezogabine (potassium channel opener, FDA-approved for focal seizures) increases M-current by enhancing Kv7 channel opening. Case reports suggest benefit in KCNQ2 encephalopathy, though evidence is limited. Cardiac monitoring required (QT prolongation risk).

Gene Therapy

KCNQ2 is an excellent gene therapy target:

• Small coding sequence (~1.8kb) easily fits in AAV
• Loss-of-function mechanism (50% expression likely beneficial)
• Early intervention before developmental regression is critical

Research and Open Questions

References

Pathway Diagram

The following diagram shows the key molecular relationships involving KCNQ2 discovered through SciDEX knowledge graph analysis: